Predictors of radiographic erosion and joint space narrowing progression in patients with early rheumatoid arthritis: a cohort study

Rydell, Emil; Forslind, Kristina; Nilsson, Jan-Åke; Karlsson, Magnus; Åkesson, Kristina E.; Jacobsson, Lennart T. H.; Turesson, Carl

doi:10.1186/s13075-020-02413-7

Table 4 Baseline predictors of joint space narrowing score progression up to 5 years

From: Predictors of radiographic erosion and joint space narrowing progression in patients with early rheumatoid arthritis: a cohort study

	Crude		Adjusted^a
	β	95% CI	β	95% CI
Demographics
Male sex	0.00	− 0.13, 0.13	− 0.02	− 0.14, 0.11
Age (per SD)^b	0.06	− 0.00, 0.12	0.03^c	− 0.03, 0.10^c
Time to first DMARD (per SD)^b	− 0.01	− 0.07, 0.04	0.00	− 0.06, 0.05
Smoking habits
Never smoker (reference)	0.00		0.00
Current smoker	0.06	− 0.08, 0.21	0.10	− 0.05, 0.25
Previous smoker	0.03	− 0.12, 0.17	0.03	− 0.10, 0.17
Ever smoker	0.05	− 0.08, 0.17	0.06	− 0.06, 0.19
Baseline disease parameters
RF positivity	0.18	0.06, 0.31	0.18^d	0.06, 0.30^d
Anti-CCP positivity	0.17	0.05, 0.30	0.09	− 0.04, 0.23
COMP titer (per SD)^b	0.04	− 0.02, 0.10	0.04	− 0.03, 0.10
COMP > 12 units/l	0.08	− 0.05, 0.20	0.08	− 0.05, 0.20
Erosions present^e	0.19	0.03, 0.35	0.13^f	− 0.03, 0.29^f
Erosion score (per SD)^b	0.12	0.06, 0.17	0.11^f	0.05, 0.16^f
Joint space narrowing score (per SD)^b	0.11	0.06, 0.17	0.10^f	0.04, 0.16^f
DAS28 (per SD)^b	0.02	− 0.05, 0.08	0.01	− 0.05, 0.06
Disease activity^e
Low/moderate (reference)	0.00		0.00
High	0.10	− 0.02, 0.23	0.08	− 0.04, 0.20
HAQ (per SD)^b	0.02	− 0.04, 0.08	0.03	− 0.02, 0.09
ESR (per SD)^b	0.09	0.03, 0.15	0.06	0.003, 0.12
CRP below median (reference)	0.00		0.00
CRP above median (> 9 mg/l)	0.13	0.01, 0.25	0.07	− 0.05, 0.19
Swollen joint count (per SD)^b	0.00	− 0.06, 0.06	0.00	− 0.06, 0.06
Tender joint count (per SD)^b	− 0.07	− 0.14, − 0.003	− 0.05	− 0.13, 0.02
Patient’s global assessment (VAS; per SD)^b	0.03	− 0.03, 0.09	0.02	− 0.04, 0.08
Pain (VAS; per SD)^b	0.00	− 0.06, 0.06	0.02	− 0.04, 0.08

Numbers in bold indicate significance of p ≤ 0.05
CI confidence interval, SD standard deviation, DMARD disease-modifying anti-rheumatic drug, RF rheumatoid factor, Anti-CCP anti-citrullinated peptide antibodies, COMP cartilage oligomeric matrix protein, DAS28 disease activity score of 28 joints, HAQ health assessment questionnaire, ESR erythrocyte sedimentation rate, CRP C-reactive protein, VAS visual analogue scale, JSN joint space narrowing
^aAdjusted for RF, age and baseline JSN score
^bSD: age 15 years; time to first DMARD 5.8 months; COMP 3.6 units/l; erosion score 3; JSN score 8; DAS28 1.4; HAQ 0.64; ESR 26 mm/h; swollen joint count 4.9; tender joint count 5.8; patient’s global assessment 26; pain 26
^cAdjusted for RF and baseline JSN score
^dAdjusted for age and baseline JSN score
^eFor definitions see Table 1
^fAdjusted for RF and age

Back to article page

ISSN: 1478-6362

Contact us

General enquiries: journalsubmissions@springernature.com

Arthritis Research & Therapy

Contact us